Scheen AJ, Paquot N. Traitement des patients diabétiques de type 2 à risque cardio-rénal : ADA-EASD versus ESC. Rev Med Suisse 2020; 16:1478-82.
Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J 2020; 41:111-88.
Devroey D, Radermecker RP, Van der Schueren BJ, et al. Prevalence of Persistent Lipid Abnormalities in Statin-Treated Patients: Belgian Results of the Dyslipidaemia International Study (DYSIS). Int J Clin Pract 2014; 68:180-7.
Hermans MP, Gevaert S, Descamps O, et al. Frequency and Predictors of Cholesterol Target Attainment in Patients with Stable Coronary Heart Disease in Belgium: Results from the Dyslipidemia International Study II. Acta Clin Belg 2019; 74:399-404.
Radermecker RP, Scheen AJ. Comment optimaliser le traitement hypolipidémiant : ne pas oublier la problématique du défaut d observance. Rev Med Liège 2010; 65:311-7.
Singh M, McEvoy JW, Khan SU, et al. Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines Vs The ESC/EAS Guidelines. Mayo Clin Proc 2020; 95:998-1014.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:1083-143.
Tecce N, Masulli M, Lupoli R, et al. Evaluation of Cardiovascular Risk in Adults with Type 1 Diabetes: Poor Concordance Between the 2019 ESC Risk Classification and 10-Year Cardiovascular Risk Prediction According to the Steno Type 1 Risk Engine. Cardiovasc Diabetol 2020; 19:166.
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract 2017; 23:1-81.
Amor AJ, Ortega E, Giménez M, et al. Prevalence and Factors Associated with Statin Use in High-Risk Patients with Type 1 Diabetes From a Specialized Diabetes Unit, Endocrinología, Diabetes y Nutrición (English ed.) 2019; 66:512-9.
Rawshani A, Rawshani A, Sattar N, et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation 2019; 139:1900-12.
Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. Lancet 2010; 375:2215-22.
Secrest AM, Becker DJ, Kelsey SF, et al. Cause-Specific Mortality Trends in a Large Population-Based Cohort with Long-Standing Childhood-Onset Type 1 Diabetes. Diabetes 2010; 59:3216-22.
Weis U, Turner B, Gibney J, et al. Long-Term Predictors of Coronary Artery Disease and Mortality in Type 1 Diabetes. QJM 2001; 94:623-30.
Zgibor JC, Ruppert K, Orchard TJ, et al. Development of a Coronary Heart Disease Risk Prediction Model for Type 1 Diabetes: The Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Res Clin Pract 2010; 88:314-21.
Maahs DM, Ogden LG, Dabelea D, et al. Association of Glycaemia with Lipids in Adults wth Type 1 Diabetes: Modification by Dyslipidaemia Medication. Diabetologia 2010; 53:2518-25.
Vergès B. Dyslipidemia in Type 1 Diabetes: A Masked Danger. Trends Endocrinol Metab 2020; 31:422-34.
Perségol L, Foissac M, Lagrost L, et al. HDL Particles from Type 1 Diabetic Patients Are Unable to Reverse the Inhibitory Effect of Oxidised LDL on Endothelium-Dependent Vasorelaxation. Diabetologia 2007; 50:2384-7.
Renard C, Fredenrich A, Van Obberghen E. L athérosclérose accélérée chez les patients diabétiques. Métabolismes Hormones Diabètes et Nutrition 2004; 8:131-6.
Sousa GR, Pober D, Galderisi A, et al. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. Circulation 2019; 139:730-43.
